Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Yamazaki, Kentaro; Yamanaka, T.; Shiozawa, Manabu; Manaka, Dai; Kotaka, Masahito; Gamoh, Makio; Shiomi, Akio; Makiyama, Akitaka; Munemoto, Yoshinori; Rikiyama, Toshiki; Fukunaga, Masao; Ueki, Takashi; Shitara, Kohei; Shinkai, Hiroshi; Tanida, Nobuyuki; Oki, Eiji; Sunami, Eiji; Ohtsu, Atsushi; Maehara, Yoshihiko; Yoshino, Takayuki

doi:10.1016/j.annonc.2020.10.480

Cited by 34 publications

(28 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the latest data released by the National Cancer Center , there are 387,600 new cases of colon cancer in China in 2015, accounting for 9.87% of all malignant tumors. Colon cancer caused 187,100 deaths, accounting for 8.01% of all cancer deaths [ 1 – 3 ]. Most cases occur after the age of 40 years old, and the male to female ratio is 2 : 5.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of rCCK96-104PE38 Targeted Drug in the General Surgical Treatment of Colon Cancer

Cao

Zhang

Liu

2022

BioMed Research International

View full text Add to dashboard Cite

To evaluate the clinical efficacy and safety of the rCCK96-104PE38 targeted drug in patients with colon cancer in general surgery, data of 80 patients with colon cancer who were admitted to the hospital from April 2019 to July 2021 were selected and randomly divided into the treatment group and the control group, with 40 cases in each group. Patients in the treatment group were treated with the rCCK96-104PE38 targeted drug, and those in the control group were treated with oxaliplatin. The treatment efficiency and incidence of adverse reactions were compared between the two groups. The inverse cholecystokinin (CCK96-104) was fused with pseudomonas aeruginosa exotoxin (PE38 toxin) through the gene amplification technique to construct a prokaryotic expression vector. Then, the rCCK96-104PE38 was purified by Ni-nitrilotriacetate (Ni-NTA) affinity chromatography, and the antitumor activity of rCCK96-104PE38 was verified. The results showed that the amplified rCCK96-104PE38 sequence was correct and the pET-28a prokaryotic expression system was adopted to successfully achieve active expression. The purified recombinant protein could induce the apoptosis of colon cancer cells in vitro and inhibit tumor growth in vivo. The total effective rate in the treatment group (80%, 32/40) was higher than that in the control group (60%, 24/40) ( P < 0.05 ). To sum up, the recombinant toxin rCCK96-104PE38 could not only specifically adsorb the colon cancer cells with high expression of CCK2R but also effectively inhibit tumor tissue growth and proliferation. Besides, the rCCK96-104PE38 protein had a good anticancer effect that helped effectively reduce the incidence of adverse reactions in patients, which was worthy of promoting.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of rCCK96-104PE38 Targeted Drug in the General Surgical Treatment of Colon Cancer

Cao

Zhang

Liu

2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…15 In addition, in the AHIEVE-2 trial, which compared the 3-month with 6-month CAPOX or mFOLFOX6 regimens as adjuvant treatment, the non-inferiority of 3-month treatments was not shown and the 3-year disease-free survival (DFS) rate inT4 stage patients was less favorable in the 3-month treatments than in the 6-month treatments (3-month 76.2% vs. 6 month 79.7%, HR 1.28 [0.68-2.43]). 16 The 6-month oxaliplatin-based regimen might improve the prognosis in both BD3 and T4 stage patients.…”

Section: Discussionmentioning

confidence: 99%

Association Between Tumor Budding Grade and T Stage in Predicting Recurrence in High-risk Stage Ii Colorectal Cancer

Kodama

Yamaguchi

Ishizuka

et al. 2021

Preprint

View full text Add to dashboard Cite

In pathological stage (pStage) II colon cancer, factors such as T stage (T) are high-risk features (HRF) for recurrence. The SACURA trial showed that tumor budding (BD) grade was also associated with recurrence: the 5-year recurrence-free survival (RFS) rate was lower in patients in the BD3 group compared with that of other groups. Interestingly, the BD3 group had a higher proportion of patients with T4. We investigated the prognostic association between T4 and BD3 for recurrence in pStage II colorectal cancer (pII-CRC) with HRF. We analyzed pII-CRC patients with HRF between 2013–2018 at our hospital, Japan. Inclusion criteria were as follows: ≥1 HRF [<12 lymph nodes examined (<12LN), lymph/vascular-invasion, perineural-invasion, T, BD, and histologic-type]. We primarily analyzed the relationship between each factor and RFS. Among 2,920 pII-CRC patients, 448 had HRF. Of these, 43 (9.6%) had T4 and 236 (52.7%) had BD3. On initial analysis, <12LN (P=0.0412), tumor location (P=0.0023), T4 (P=0.0023), and BD3 (P=0.0396) were independent prognostic factors for RFS. Among 257 patients with BD3 and/or T4, the 5-year RFS rates were 81.3%, 74.6%, and 66.2% for patients with BD3 (214 patients), T4 (22 patients), and BD3 plus T4 (21 patients), respectively (hazard ratio 3.08, P=0.0079). pII-CRC patients with BD3 plus T4 had poorer prognosis than those with other factors.

show abstract

“…The ACHIEVE-II trial enrolled 525 patients from Japan with high-risk stage II CC to three-versus six-month treatment with either CAPOX or mFOLFOX6. 15 In the patients receiving CAPOX, the three-year DFS rate was 88.2% in the three-month group and 87.9% in the six-month group (HR, 1.12; 95% CI, 0.67 -1.87). Notably, the incidence of grade 2 or worse peripheral neuropathy was higher in the six month arm (16% and 43%, respectively, P < .0001).…”

Section: Jesus C Fabregas Et Almentioning

confidence: 92%

Clinical Updates for Colon Cancer Care in 2022

Fabregas

Ramnaraign

George

2022

Clinical Colorectal Cancer

View full text Add to dashboard Cite

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Cited by 34 publications

References 19 publications

Efficacy and Safety of rCCK96-104PE38 Targeted Drug in the General Surgical Treatment of Colon Cancer

Efficacy and Safety of rCCK96-104PE38 Targeted Drug in the General Surgical Treatment of Colon Cancer

Association Between Tumor Budding Grade and T Stage in Predicting Recurrence in High-risk Stage Ii Colorectal Cancer

Clinical Updates for Colon Cancer Care in 2022

Contact Info

Product

Resources

About